← Back to Directory

GLP-1 Receptor Agonists

Incretin Mimetics, GLP-1 RAs

Visual ViewRaw DataInteraction Data

Meta Information

ID:glp-1-receptor-agonists
Name:GLP-1 Receptor Agonists
Schema Version:1.5

Alternate Names

  • Incretin Mimetics
  • GLP-1 RAs

Active Compound

null

Intervention Type

therapeutic_agent

Delivery

Route:
multiple
Scope:
  • systemic

Regulatory Status

  • us:rx_drug
  • eu:rx_drug

Indication

Focus:
healthspan
Description:
Targets metabolic health by improving glucose control, promoting significant weight loss, and reducing major adverse cardiovascular events in at-risk populations.

Typical Protocol

  • Typically administered via weekly subcutaneous injections, with doses titrated up over several months to manage side effects.
  • Oral formulations are available for some agents and are typically taken daily.

Expected Cost Mean

Low Cost:
900
High Cost:
1500
Cost Type:
monthly
Description:
High out-of-pocket cost; insurance coverage varies widely based on specific diagnosis.

Summary

GLP-1 Receptor Agonists mimic the native incretin hormone GLP-1, which enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and acts on the brain to reduce appetite and food intake. These combined actions lead to substantial weight loss and improved glycemic control, which are foundational for extending healthspan by mitigating the progression of metabolic diseases.

Purpose

Mimics gut hormones to improve metabolic health and induce weight loss.

Card Summary

A class of injectable or oral drugs that powerfully regulate blood sugar and appetite, leading to significant weight loss and improved metabolic function.

Drug Class

Drugs In Class

  • retatrutide
  • semaglutide
  • tirzepatide

Impact

Score:
8.5
Justification:
Profound, systemic improvements in metabolic health, weight, and established cardiovascular risk reduction.

Evidence

Grade:
A
Score:
9.5
Justification:
Extensive, large-scale human RCTs and meta-analyses confirm significant metabolic and cardiovascular benefits.

Safety

Score:
5.5
Justification:
Common GI side effects; rare but serious risks require medical supervision.

Flags

  • Common side effects include nausea, vomiting, diarrhea, and constipation, especially during dose escalation.
  • Risk of pancreatitis, gallbladder disease, and gastroparesis (stomach paralysis) has been reported.
  • Boxed warning for risk of thyroid C-cell tumors based on rodent studies; relevance to humans is uncertain.
  • Potential for significant loss of lean muscle mass alongside fat mass, requiring mitigation strategies like resistance training.
  • Rapid weight regain is common after discontinuation of the medication.
  • Contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2.

Verdict

Highly effective for metabolic health and weight loss, but requires medical supervision.

Qualifier

A class of drugs including incretin mimetics (semaglutide, tirzepatide) focused on metabolic health and weight loss.

Created

2026-04-29T21:03:57.122215Z

Ai Model

Gemini 2.5 Pro (High)